Page 1

14 September 2021 Diaceutics PLC ( AIM : DXRX ) , the diagnostic commercialisation company , announces its unaudited interim results for the six months ended 30 June 2021 . Financial highlights Revenue ( £ m ) Gross profit ( Em ) Gross margin EBITDA ( £ m ) Diaceutics PLC ( " Diaceutics " , the " Company " or the " Group " ) Half Year Report ( Loss ) / profit before tax ( £ m ) Net cash ( £ m ) Earnings per share ( pence ) ● H1 2021 6.0 4.4 74 % 0.3 ( 0.5 ) 23.7 0.40 Operational highlights H1 2020 5.3 3.8 71 % 0.3 0.03 29.8 1.52 Positive first half performance despite the challenging COVID - 19 headwinds , with growth in Revenue , Gross margin , and a positive EBITDA Revenue increased by 13 % to £ 6.0m ( H1 2020 : £ 5.3m ) or 24 % on a constant currency basis ● The DXRX platform contributed 44 % of total revenue in H1 2021 , well ahead of the Board's target at the beginning of the year of 20 % of full year revenue to be generated via the platform Reported Gross margin increased by 4 % in comparison to the comparative period EBITDA , of £ 0.3m ( H1 2020 : £ 0.3m ) net of investments during H1 in business development , sales commission , and legal and professional costs Loss before tax of £ 0.5m ( H1 2020 : Profit £ 0.03m ) which is primarily driven by an expected increase in amortisation as a result of the DXRX platform launch on 28 October 2020 ● Closing cash position of £ 23.7m ( H1 2020 : £ 29.8m ) 15 pharmaceutical clients now engaged on the DXRX platform • DXRX's second phase launch on track for H2 2021 for four additional modules ● Contracts with 33 clients for H1 2021 ( H1 2020 : 29 ) , and 48 brands ( H1 2020 : 42 ) with the addition of two new clients , one of which is our first diagnostic client